Guardant Health just smashed Q2 earnings with $335M in revenue—up 44% YoY and beating Wall Street—while boosting its full-year forecast to $1.35B. Their liquid biopsy tech, which detects cancer via blood tests, is gaining traction, driving stock up nearly 7%. Though EPS missed estimates and the company still runs a loss, margins are tightening and growth momentum remains strong. A standout player in cancer diagnostics with serious upside.
Listen in comfort: Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn.
Advertise on DNN: advertise@thednn.ai
This is an automated, high-level news summary based on public reporting. Report issues to feedback@thednn.ai.
Podden och tillhörande omslagsbild på den här sidan tillhör
The Daily News Now!. Innehållet i podden är skapat av The Daily News Now! och inte av,
eller tillsammans med, Poddtoppen.
